olanzapine and melatonin

PreclinicalSmall molecule

SSeattle Institute for Biomedical and Clinical Research

olanzapine and melatonin is one of 25 small molecule programs targeting Schizoaffective Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Schizoaffective DisorderActive, not recruiting

Schizoaffective DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Schizoaffective Disorder

#DrugCompanyPhaseTrials

Risperdal

WWim Janssens

Approved

18 2

Zyprexa

MMODAG GmbH

Approved

10 3

Nicorette

Pfizer

Approved

1 4

Depakote

Teva

Approved

1 5

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

8 6

Abilify

Otsuka

Approved

6 7

Epidiolex

Estrace

Diamox

Haldol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizoaffective Disorder1 trial

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

Completed·SSeattle Institute for Biomedical and Clinical Research·N/A·NCT00512070·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for olanzapine and melatonin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — olanzapine and melatonin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for olanzapine and melatonin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seattle Institute for Biomedical and Clinical Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeattle Institute for Biomedical and Clinical Research

olanzapine and melatonin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizoaffective Disorder1 trial

References

Drug Info

Quick Facts

Related News